Disordered purinergic signaling inhibits pathological angiogenesis in Cd39/Entpd1-null mice

American Journal of Pathology

Volumn 171, Issue 4, 2007, Pages 1395-1404

  Jackson, Shaun W ^a,d   Hoshi, Tomokazu ^b   Wu, Yan ^a   Sun, Xiaofeng ^a   Enjyoji, Keiichi ^a   Cszimadia, Eva ^a   Sundberg, Christian ^c   Robson, Simon C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD39 ANTIGEN; FOCAL ADHESION KINASE; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER TRANSPLANTATION; CELL ADHESION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE DELETION; IMMUNOPATHOLOGY; IN VITRO STUDY; LUNG METASTASIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 35348839497     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2007.070190     Document Type: Article

References (30)

1. Kaczmarek E, Koziak K, Sevigny J, Siegel JB, Anrather J, Beaudoin AR, Bach FH, Robson SC: Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 1996, 271:33116-33122
2. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, Williams M: Nomenclature and classification of purinoreceptors. Pharmacol Rev 1994, 46:143-152
3. Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch JS, Imai M, Edelberg JM, Rayburn H, Lech M, Beeler DL, Csizmadia E, Wagner DD, Robson SC, Rosenberg RD: Targeted disruption of Cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999, 5:1010-1017
4. Satterwhite CM, Farrelly AM, Bradley ME: Chemotactic, mitogenic, and angiogenic actions of UTP on vascular endothelial cells. Am J Physiol 1999, 45:H1091-H1097
5. Goepfert C, Sundberg C, Sevigny J, Enjyoji K, Hoshi T, Csizmadia E, Robson SC: Disordered cellular migration and angiogenesis in Cd39-null mice. Circulation 2001, 104:3109-3115
6. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364
7. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257
8. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389-395
9. Hodivala-Dilke KM, Reynolds AR, Reynolds LE: Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res 2003, 314:131-144
10. o-mediated signal transduction. J Cell Biol 2001, 153:491-501
11. Parsons JT: Focal adhesion kinase: the first ten years. J Cell Sci 2003, 116:1409-1416
12. Berra E, Milanini J, Richard DE, Le Gall M, Vinals F, Gothie E, Roux D, Pages G, Pouyssegur J: Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 2000, 60:1171-1178
13. Shih IM, Torrance C, Sokoll LJ, Chan DW, Kinzler KW, Vogelstein B: Assessing tumors in living animals through measurement of urinary β-human chorionic gonadotropin. Nat Med 2000, 6:711-714
14. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T: Antitumor activity of IFN-λ in murine tumor models. J Immunol 2006, 176:7686-7694
15. Maeshima Y, Colorado PC, Torre A, Holthaus KA, Grunkemeyer JA, Ericksen MB, Hopfer H, Xiao Y, Stillman IE, Kalluri R: Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem 2000, 275:21340-21348
16. 3-Integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999, 103:229-238
17. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH: Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000, 96:3302-3309
18. Kaczmarek E, Erb L, Koziak K, Jarzyna R, Wink MR, Guckelberger O, Blusztajn JK, Trinkaus-Randall V, Weisman GA, Robson SC: Modulation of endothelial cell migration by extracellular nucleotides: involvement of focal adhesion kinase and phosphatidylinositol 3-kinase-mediated pathways. Thromb Haemost 2005, 93:735-742
19. 3-integrins. J Biol Chem 1994, 269:960-967
20. 3. Clin Cancer Res 2000, 6:3056-3061
21. 5 integrins. Nat Med 2002, 8:27-34
22. Carmeliet P: Integrin indecision. Nat Med 2002, 8:14-16
23. Pierce KL, Premont RT, Lefkowitz RJ: Signalling: seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002, 3:639-650
24. Hall RA, Lefkowitz RJ: Regulation of G protein-coupled receptor signaling by scaffold proteins. Circ Res 2002, 91:672-680
25. Wu Y, Sun X, Kaczmarek E, Dwyer KM, Bianchi E, Usheva A, Robson SC: RanBPM associates with CD39 and modulates ecto-nucleotidase activity. Biochem J 2006, 396:23-30
26. Wang D, Li Z, Messing EM, Wu G: Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM. J Biol Chem 2002, 277:36216-36222
27. Denti S, Sirri A, Cheli A, Rogge L, Innamorati G, Putignano S, Fabbri M, Pardi R, Bianchi E: RanBPM is a phosphoprotein that associates with the plasma membrane and interacts with the integrin LFA-1. J Biol Chem 2004, 279:13027-13034
28. 2A receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. Am J Pathol 2004, 164:1887-1892
29. 2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 2006, 103:13132-13137
30. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC: Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007, 204:1257-1265